← Leaderboards
Rangan Maitra
Research Triangle Institute
$14,311,381
Attributed
$16,448,005
Total exposure
13
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2007–25$2.5M$1.9M$1.3M$625K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$16,448,005 · 13
By mechanism
R01$12,802,274 · 7
N01$2,060,112 · 1
R21$1,015,986 · 3
U18$352,851 · 1
R03$216,782 · 1
Top collaborators
- Scott P Runyon5 shared
- Yanan Zhang3 shared
Most similar at Research Triangle Institute
Same institution · by research overlap
- Scott P Runyon$6,910,265
- Brian F Thomas$3,550,619
- Yanan Zhang$8,086,410
Others in their field
Top investigators on “Reporting”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Jeffrey P Krischer · University Of South Florida$564,567,727
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Bambra Strokes · Ppd Development Lp$461,655,950
- Mitchell J Malone · Texas A&M Research Foundation$344,583,004
- Gary D Acton · University Of California-Davis$320,373,312
Research focus
ReportingAgonistPharmaceutical PreparationsLeadIn VitroDrug KineticsDesignReceptorAdverse EffectsIn VivoLigandsProteinsBiological MarkersCellsScaffoldEndocannabinoidsEfficacy TestingChronicPropertyRodentEnzymesPenetrationPeripheralCannabinoid Receptor
Grant awards (39)
HIV Assay Development and Testing to Identify Targeted Activator of Cell Kill Molecules$1,088,954
N01 · FY2025 · AI · contact PI
In Vivo Probes of Mas1 Receptor$641,438
R01 · FY2025 · MH · contact PI
Investigation of Synthetic Cannabinoid Exposures and Pharmacological Consequences$562,088
R01 · FY2025 · DA · contact PI
In Vivo Probes of Mas1 Receptor$636,641
R01 · FY2024 · MH · contact PI
HIV Assay Development and Testing to Identify Targeted Activator of Cell Kill Molecules$391,596
N01 · FY2024 · AI · contact PI
Investigation of Synthetic Cannabinoid Exposures and Pharmacological Consequences$579,418
R01 · FY2023 · DA · contact PI
Novel therapeutic approach for NASH$517,984
R01 · FY2023 · DK · contact PI
Conduct Confirmatory and Specialized In Vitro Testing and Screening of Interventional Agents in Standard Formats$334,662
N01 · FY2023 · AI · contact PI
Conduct In Vitro Screening of Interventional Agents in High Throughput Screening (HTS) Formats: High Throughput Screening to Identify HIV Inhibitors$227,601
N01 · FY2023 · AI · contact PI
Investigation of Synthetic Cannabinoid Exposures and Pharmacological Consequences$567,172
R01 · FY2022 · DA · contact PI
Novel therapeutic approach for NASH$517,984
R01 · FY2022 · DK · contact PI
Novel therapeutic approach for NASH$517,984
R01 · FY2021 · DK · contact PI
APJ receptor agonism for metabolic syndrome$486,222
R01 · FY2021 · DK · contact PI
Preclinical Services for HIV Therapeutics: QA/QC Plan and Task Order Initiation Meeting$17,299
N01 · FY2021 · AI · contact PI
Novel therapeutic approach for NASH$517,984
R01 · FY2020 · DK · contact PI
APJ receptor agonism for metabolic syndrome$486,222
R01 · FY2020 · DK · contact PI
Strategy for synthetic cannabinoid abuse and toxicity$352,851
U18 · FY2020 · DA · contact PI
APJ receptor agonism for metabolic syndrome$486,222
R01 · FY2019 · DK · contact PI
APJ receptor agonism for metabolic syndrome$486,222
R01 · FY2018 · DK · contact PI
Peripheralized CB1 antagonists for ALD$451,358
R01 · FY2018 · AA · contact PI
APJ receptor agonism for metabolic syndrome$471,450
R01 · FY2017 · DK · contact PI
Peripheralized CB1 antagonists for ALD$451,404
R01 · FY2017 · AA · contact PI
Therapeutics Development for Hepatic Fibrosis$448,433
R01 · FY2017 · DK · contact PI
Peripheralized CB1 antagonists for ALD$451,383
R01 · FY2016 · AA · contact PI
Therapeutics Development for Hepatic Fibrosis$449,130
R01 · FY2016 · DK · contact PI
In vivo probes for the APJ receptor.$435,653
R01 · FY2016 · HD · contact PI
Therapeutics Development for Hepatic Fibrosis$449,428
R01 · FY2015 · DK · contact PI
Peripheralized CB1 antagonists for ALD$437,968
R01 · FY2015 · AA · contact PI
In vivo probes for the APJ receptor.$423,010
R01 · FY2015 · HD · contact PI
Peripheralized CB1 antagonists for ALD$451,504
R01 · FY2014 · AA · contact PI
Therapeutics Development for Hepatic Fibrosis$450,143
R01 · FY2014 · DK · contact PI
In vivo probes for the APJ receptor.$427,829
R01 · FY2014 · HD · contact PI
Peripherally Selective CB1 Receptor Antagonists for Alcoholic Liver Disease$287,770
R21 · FY2011 · AA · contact PI
Peripherally Selective CB1 Receptor Antagonists for Alcoholic Liver Disease$273,333
R21 · FY2010 · AA · contact PI
Anti-inflammatory Assay for Cystic Fibrosis$52,233
R21 · FY2010 · NS · contact PI
High-throughput Assay to Identify CFTR Inhibitors$199,104
R21 · FY2009 · NS · contact PI
Peripherally Active CB1 Receptor Antagonists for Alcohol-Induced Liver Fibrosis$108,388
R03 · FY2009 · AA · contact PI
Peripherally Active CB1 Receptor Antagonists for Alcohol-Induced Liver Fibrosis$108,394
R03 · FY2008 · AA · contact PI
Anti-inflammatory Assay for Cystic Fibrosis$203,546
R21 · FY2007 · NS · contact PI